ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
70,179.15
2.43%
S&P 500
5,304.72
0.70%
Dow Jones
39,069.59
0.01%
US Dollar vs Yen
156.885
-0.05%
Brent Oil
82.845
1.06%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Neoleukin Therapeutics Inc (NLTX)

  7. Neoleukin Therapeutics Inc (NLTX) ニュース

NLTX

Neoleukin Therapeutics (NLTX)

Neoleukin Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NLTX
日付受信時刻ニュースソース見出しコード企業名
2024/05/1105 : 14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NLTXNeoleukin Therapeutics Inc
2024/05/1020 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/05/0719 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/04/2703 : 34Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/04/2703 : 33Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/04/2703 : 33Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/04/2305 : 44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/04/0304 : 43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/1905 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/1905 : 04Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/1509 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/1509 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/1509 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/0806 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/0508 : 20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/03/0421 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/2206 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/2106 : 16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/1508 : 05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/1506 : 26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/1506 : 16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/1505 : 08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/1423 : 19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NLTXNeoleukin Therapeutics Inc
2024/02/0706 : 18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1909 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1908 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1908 : 56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1908 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1908 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
2024/01/1908 : 45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NLTXNeoleukin Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NLTX

最近閲覧した銘柄

NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
USOTC
BASFY
BASF (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USI
USTECH100
US Tech 100
NYSE
NKE
Nike
NASDAQ
MSFT
Microsoft
AMEX
XLV
Health Care Select Sector
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
AMEX
XLE
Energy Select Sector SPDR
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有